A major trial of a promising gene therapy for Duchenne muscular dystrophy has fallen short, but researchers say the lessons learned could pave the way for better, more effective treatments.

Sarepta Therapeutics (NASDAQ:SRPT) stock draws an Overweight rating at Wells Fargo, based on commercial prospects for ...

Sarepta Therapeutics SRPT announced updates from its clinical programs, which focus on targeting different subtypes of limb-girdle muscular dystrophy (LGMD), a group of rare genetic disorders marked ...

Wells Fargo initiated coverage of Sarepta (SRPT) with an Overweight rating and $115 price target Despite the recent Gr5 AE case, the firm ...

In other recent news, Sarepta Therapeutics has been the focus of several analyst updates and regulatory developments concerning its gene therapy, ELEVIDYS, for Duchenne muscular dystrophy (DMD).

In other recent news, Sarepta Therapeutics has been the focus of several analyst updates and regulatory developments concerning its gene therapy, ELEVIDYS, for Duchenne muscular dystrophy (DMD). Wells ...

The Parent Project Muscular Dystrophy (PPMD ... Three studies of Sarepta's Elevidys Duchenne gene therapy have been placed on hold as the death of a 16-year-old boy is investigated.

The death of a patient treated with Sarepta's Duchenne muscular dystrophy (DMD) gene therapy Elevidys has played havoc with its share price – although analysts believe that its benefits still ...

The best performers in the group are the Averill funds. Averill was down 2.9 percent in March but just 0.9 percent in the ...